Michael C. Quirk - 24 Jun 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Scientific Officer and Interim Head of R&D
Signature: Brandon Marsh, attorney in fact for Michael C. Quirk
Issuer symbol: SAGE
Transactions as of: 24 Jun 2025
Net transactions value: -$1,042
Form type: 4
Filing time: 26 Jun 2025, 16:02:27 UTC
Previous filing: 11 Apr 2025
Next filing: 31 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Quirk Michael C.	Chief Scientific Officer and Interim Head of R&D	C/O SAGE THERAPEUTICS, INC., 55 CAMBRIDGE PARKWAY, CAMBRIDGE	Brandon Marsh, attorney in fact for Michael C. Quirk	26 Jun 2025	0002063117

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Tax liability	$1,042	-113	-0.37%	$9.22	30,461	24 Jun 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 24, 2025, the reporting person vested 338 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Content

On June 24, 2025, the reporting person vested 338 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Remarks:

Chief Scientific Officer and Interim Head of R&D